Edesa Biotech Inc $ 4.93 -0.28 (-5.42%)
Warning! GuruFocus has detected 3 Severe warning signs with EDSA. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for EDSA (Edesa Biotech Inc) from 2010 to Dec 02 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Edesa Biotech stock (EDSA) PE ratio as of Dec 02 2020 is 0. More Details
Edesa Biotech PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Edesa Biotech PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:TTNP NAS:ALRN NAS:AIKI NAS:SLS AMEX:NBY OTCPK:RGRX NAS:CYCC OTCPK:IGXT NAS:OCGN NAS:NTRP OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.